Lirit N. Franks

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies

Kathryn A. Seely, Lisa K. Brents, Lirit N. Franks et al. · Neuropharmacology · 2012 · 101 citations

Medicine, Pharmacology, Molecular Pharmacology +15

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors

Maheswari Rajasekaran, Lisa K. Brents, Lirit N. Franks et al. · Toxicology and Applied Pharmacology · 2013 · 90 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner

Shidie Tai, William S. Hyatt, Congwei Gu et al. · Pharmacological Research · 2015 · 50 citations · Full text

Medicine, Neuroscience, Pharmacology +12

Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development

Benjamin M. Ford, Lirit N. Franks, Sherrica Tai et al. · Pharmacological Research · 2017 · 41 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse

Tamara Vasiljevik, Lirit N. Franks, Benjamin M. Ford et al. · Journal of Medicinal Chemistry · 2013 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15